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Better prognostic predictors for invasive candidiasis (IC) are needed to tailor 
and individualize therapeutic decision-making and minimize its high morbidity and 
mortality. We investigated whether molecular profiling of IgG-antibody response to the 
whole soluble Candida proteome could reveal a prognostic signature that may serve to 
devise a clinical-outcome prediction model for IC and contribute to known IC 
prognostic factors. By serological proteome analysis and data-mining procedures, serum 
31-IgG antibody-reactivity patterns were examined in 45 IC patients randomly split into 
training and test sets. Within the training cohort, unsupervised two-way hierarchical 
clustering and principal-component analyses segregated IC patients into two antibody-
reactivity subgroups with distinct prognoses that were unbiased by traditional IC 
prognostic factors and other patients-related variables. Supervised discriminant analysis 
with leave-one-out cross-validation identified a 5-IgG antibody-reactivity signature as 
the most simplified and accurate IC clinical-outcome predictor, from which an IC 
prognostic score (ICPS) was derived. Its robustness was confirmed in the test set. 
Multivariate logistic regression and receiver-operating-characteristic curve analyses 
demonstrated that the ICPS was able to accurately discriminate IC patients at high-risk 
for death from those at low-risk and outperformed conventional IC prognostic factors. 
Further validation of the 5-IgG antibody-reactivity signature on a multiplexed 
immunoassay supported the serological proteome analysis results. We conclude that the 
ICPS, with additional refinement in future larger prospective cohorts, could be 
applicable to reliably predict patient clinical-outcome for individualized therapy of IC. 
Our data further provide insights into molecular mechanisms that may influence clinical 
outcome in IC and uncover potential targets for vaccine design and immunotherapy 
against IC. 
